Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Since its spin-off from Abbott Laboratories in 2013, AbbVie has delivered strong dividend growth.

AbbVie: A Trifecta Of Yield, Growth, And Total Return Potential

3 Reasons AbbVie Is Ready To Bounce

Brookfield Infrastructure Partners L.P.

Duke Energy

You can sleep tight while the dividends pour in with these three stocks.

3 Dividend Stocks Yielding More Than 4% That Are Safe Buys Right Now

Eastman Chemical

Enbridge

Enterprise Products Partners

GenMark Diagnostics

Altria

Microsoft

Prudential Financial

Teladoc

Investing For The Long Run: Navigating A Bifurcated Market

AbbVie's (ABBV) key drug, Humira is seeing strong demand in the United States while generics are eroding ex-U.S. sales. New drugs Skyrizi and Rinvoq are seeing strong sales uptake.

AbbVie Outperforms Large-Cap Pharma Industry Year to Date

NORTH CHICAGO, Ill., Aug. 12, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the publication of results from the Phase 3 VIALE-A clinical study in patients with AML in the New England Journal of Medicine (NEJM).

New England Journal of Medicine Publishes Positive Phase 3 Data of Venetoclax Combination in Acute Myeloid Leukemia (AML) Patients

AstraZeneca

Johnson & Johnson

Eli Lilly

Merck

Novartis

Pfizer

Large-Cap Pharma Industry Outlook Dull Amid Coronavirus Woes

AbbVie: Another Opportunity

Federal Realty Investment Trust

MetLife

Realty Income Corp

South Jersey Industries

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

The benchmark 10-year Treasury note yields just around 0.

7 Safe High-Yield Dividend Stocks Delivering 4% or More

5 Safe Ultra-High-Yield Blue-Chips For A Rich Retirement

Amgen

Boston Scientific

New products mean solid revenue may be ahead for these companies.

3 Top Healthcare Stocks to Buy in August

Teva Pharmaceutical

These pharmaceutical giants are already preparing for the possibility of medical marijuana legalization.

3 Big Pharma Stocks With Surprising Cannabis Connections

AbbVie Inc has agreed to pay $24 million to settle a lawsuit that alleged insurance fraud by the drugmaker in promoting its blockbuster drug Humira, California's insurance regulator said on Thursday.

AbbVie agrees to pay $24 million to resolve Humira California lawsuit

AmerisourceBergen

Aflac

AvalonBay Communities

Broadcom

Bristol-Myers

CVS Health

General Dynamics

Intel

Reinsurance Group of America

Snap-on

Simon Property Group

STORE Capital

Toronto-Dominion Bank

The time has come for us to look at just what sort of companies may be appealing to invest in during August.

August 2020 Stocks - Financials, Real Estate, Industrials, IT And Pharma

ASGN

Great Lakes Dredge & Dock

Tensions between the U.S. and China continued to aggravate as the latter poured accusations of bullying over the forced sale of TikTok’s U.S.

Top Stocks To Buy Today Amid Soaring US-China Tensions

Takeda Pharmaceutical

AbbVie Inc. ABBV, -1.17% , Amgen Inc. AMGN, -0.59% , and Takeda Pharmaceutical Co.

AbbVie, Amgen and Takeda start testing drugs as COVID-19 treatments

The stock trades with a single-digit multiple despite strong growth rates from products outside of Humira

The Market Continues to Undervalue AbbVie

AbbVie Inc. (ABBV) CEO Rick Gonzalez on Q2 2020 Results - Earnings Call Transcript

AbbVie (ABBV) beats on second-quarter 2020 earnings and revenues. Shares up in pre-market trading.

AbbVie's (ABBV) Q2 Earnings and Revenues Beat Estimates

Here's how the big drugmaker fared in its first quarterly update with Allergan under its wing.

5 Key Things You'll Want to Know About AbbVie's Q2 Update

AbbVie Inc on Friday posted a quarterly adjusted profit above estimates as robust sales of its blockbuster arthritis treatment, Humira, helped cushion weak demand for its aesthetic drugs, including Botox, due to the COVID-19 pandemic.

AbbVie's Humira powers profit beat as COVID-19 weighs on Botox sales

AbbVie earnings on Friday have ABBV stock slighty lower despite the company beating EPS and revenue estimates from Wall Street.
The post AbbVie Earnings: ABBV Stock Drops 2% Despite Q2 Beats appeared first on InvestorPlace.

AbbVie Earnings: ABBV Stock Drops 2% Despite Q2 Beats

AbbVie (ABBV) delivered earnings and revenue surprises of 4.46% and 2.99%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

AbbVie (ABBV) Q2 Earnings and Revenues Beat Estimates

Shares of AbbVie Inc. ABBV, -1.00% were up 1.9% in premarket trading on Thursday after the drugmaker beat expectations for the quarter.

AbbVie shares rises on strong Q2, though cosmetic Botox sales tumbled 43%

AbbVie earnings and sales topped views. The drug giant raised full-year EPS targets including newly acquired Allergan.

AbbVie Earnings Top, Drug Giant Rebounds Bullishly, Flashes Buy Signal

News for AbbVie Stock (ABBV)